NCT01530373View on ClinicalTrials.gov

Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

July 31, 2026

Study Completion Date

September 30, 2027

Conditions
Hot FlashesBreast Cancer
Interventions
DRUG

solifenacin

oral solifenacin 5.0 mg daily for 3 weeks

DRUG

Clonidine

oral clonidine 0.1 mg daily for 3 weeks

Trial Locations (1)

722205

RECRUITING

Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock

All Listed Sponsors
lead

University of Arkansas

OTHER